Polypeptides and uses thereof for treatment of autoimmune disorders and infection
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07K-016/18
C07K-014/705
A61K-039/395
A61K-045/06
A61K-038/00
출원번호
US-0129974
(2012-07-01)
등록번호
US-9428574
(2016-08-30)
국제출원번호
PCT/IB2012/053342
(2012-07-01)
§371/§102 date
20131229
(20131229)
국제공개번호
WO2013/001517
(2013-01-03)
발명자
/ 주소
Toporik, Amir
Rosenberg, Avi Yeshah
Rotman, Galit
Hecht, Iris
Levine, Zurit
출원인 / 주소
COMPUGEN LTD.
대리인 / 주소
Graeser Associates International Inc
인용정보
피인용 횟수 :
0인용 특허 :
150
초록
This invention relates to C1ORF32 protein and its variants and fragments and fusion proteins thereof, pharmaceutical composition comprising same and methods of use thereof for treatment of immune related disorders and infections.
대표청구항▼
1. An isolated polypeptide, consisting of an amino acid sequence set forth in any one of SEQ ID NOs: 29, 42-43, 64, 68, 69, 71-87, 89, and 91-105. 2. A fusion protein comprising the polypeptide according to claim 1, fused to a heterologous sequence, directly or indirectly via a linker peptide, a pol
1. An isolated polypeptide, consisting of an amino acid sequence set forth in any one of SEQ ID NOs: 29, 42-43, 64, 68, 69, 71-87, 89, and 91-105. 2. A fusion protein comprising the polypeptide according to claim 1, fused to a heterologous sequence, directly or indirectly via a linker peptide, a polypeptide sequence or a chemical linker. 3. The fusion protein of claim 2, wherein the heterologous sequence comprises at least a portion of an immunoglobulin constant domain. 4. The fusion protein of claim 3, comprising an immunoglobulin heavy chain constant domain corresponding to an antibody isotype selected from the group consisting of an IgG1, IgG2, IgG3, IgG4, IgM, IgE, IgA and IgD. 5. The fusion protein of claim 4, wherein the immunoglobulin constant domain comprises the hinge, CH2 and CH3 regions of a human IgG immunoglobulin, selected from the group consisting of Cγ1, Cγ2, Cγ3 and Cγ4 chain. 6. The fusion protein of claim 2, further comprising a domain that mediates dimerization or multimerization of the fusion protein to form homodimers, heterodimers, homomultimers, or heteromultimers. 7. The fusion protein of claim 6, wherein the domain that mediates dimerization or multimerization is selected from the group consisting of one or more cysteines that are capable of forming an intermolecular disulfide bond with a cysteine on the partner fusion protein, a coiled-coil domain, an acid patch, a zinc finger domain, a calcium hand domain, a CHI region, a CL region, a leucine zipper domain, an SH2 (src homology 2) domain, an SH3 (src Homology 3) domain, a PTB (phosphotyrosine binding) domain, a WW domain, a PDZ domain, a 14-3-3 domain, a WD40 domain, an EH domain, a Lim domain, an isoleucine zipper domain, and a dimerization domain of a receptor dimer pair. 8. The fusion protein of claim 7, comprising an Ig Fc domain set forth in any one of SEQ ID NOs: 20, 21, 31 or 115. 9. The fusion protein of claim 8, wherein said fusion protein consists of the amino acid sequence set forth in any one of SEQ ID NOs: 29, 42-43, 64, 68, 69, 71-87, 89, and 91-105, fused to human IgG1 Fc domain set forth in any one of SEQ ID NOs: 20, 21, and 115. 10. The fusion protein of claim 9, wherein the amino acid sequence of said fusion protein is set forth in any one of SEQ ID NO: 39, 108-112, and 116-190. 11. The fusion protein of claim 10, wherein the amino acid sequence of said fusion protein is set forth in any one of SEQ ID NOs:112, 120, 110, and 136. 12. A dimeric protein comprising a first and a second fusion protein, wherein the first and the second fusion proteins comprise the fusion protein of claim 2, wherein the first and the second fusion proteins are bound to one another by covalent or noncovalent bonds to form a dimer. 13. A pharmaceutical composition comprising the polypeptide of claim 1, or a fusion protein comprising same, and a pharmaceutically acceptable diluent or carrier, adapted for treatment of any one of an autoimmune disease, graft vs host disease or transplant rejection. 14. A method for treating an immune related disorder in a subject in need thereof, comprising administering to the subject an effective amount of the polypeptide of claim 1 or a fusion protein comprising same, or pharmaceutical composition comprising same, wherein the immune related disorder is selected from the group consisting of an autoimmune disease, graft vs host disease and a transplant rejection. 15. The method of claim 14, wherein administering an effective amount of the polypeptide, or the fusion protein, or the pharmaceutical composition comprising same to the subject inhibits or reduces differentiation of, proliferation of, activity of, and/or cytokine production and/or secretion by an immune cell selected from the group consisting of Th1, Th17, and/or Th22; and/or inhibits or reduces differentiation of, proliferation of, activity of, and/or cytokine production and/or secretion by Th1, Th17 and/or Th22 cells; and/or enhances the suppressive or immunomodulatory effect of Tregs and/or Th2 cells on Th1 or Th17 cells; and/or promotes or enhances IL-10 production; and/or increases cell numbers or increases populations of any of Tregs and/or Th2 cells; and/or inhibits the Th1 and/or Th17 pathways and enhances the activity of Tregs and/or Th2 cells on the Th1 and Th17 pathways and/or to promote or enhance IL-10 secretion. 16. The method of claim 14, wherein the polypeptide, or the fusion protein, or the pharmaceutical composition comprising same is administered in an effective amount for reducing proinflammatory molecule production in a subject. 17. The method according to claim 14 further comprising administering a second therapeutic agent effective for treatment of said immune related disorder. 18. The method according to claim 14, wherein graft transplantation rejection is selected from the group consisting of acute and chronic rejection of organ transplantation, allogeneic stem cell transplantation, autologous stem cell transplantation, bone marrow transplantation, and graft versus host disease. 19. The method according to claim 14, wherein the autoimmune disease is selected from the group consisting of multiple sclerosis, rheumatoid arthritis; psoriatic arthritis, discoid lupus erythematosus, systemic lupus erythematosus (SLE); ulcerative colitis; Crohn's disease; benign lymphocytic angiitis, autoimmune lymphoproliferative syndrome, sarcoidosis, autoimmune thrombocytopenic purpura, idiopathic thrombocytopenic purpura, pure red cell aplasia, Sjogren's syndrome, rheumatic disease, polymyalgia rheumatica, inflammatory rheumatism, degenerative rheumatism, extra-articular rheumatism, juvenile arthritis, juvenile rheumatoid arthritis, systemic juvenile idiopathic arthritis, muscular rheumatism, chronic polyarthritis, reactive arthritis, Reiter's syndrome, rheumatic fever, relapsing polychondritis, Raynaud's phenomenon, vasculitis, ANCA-associated vasculitis, temporal arteritis, giant cell arteritis, Takayasu arteritis, Behcet's disease, antiphospholipid syndrome, myasthenia gravis, autoimmune haemolytic anaemia, Guillain-Barre syndrome, chronic immune polyneuropathy, chronic inflammatory demyelinating polyneuropathy, autoimmune thyroiditis, insulin dependent diabetes mellitus, type I diabetes, Addison's disease, membranous glomerulonephropathy, polyglandular autoimmune syndromes, Goodpasture's disease, autoimmune gastritis, autoimmune atrophic gastritis, pernicious anaemia, pemphigus, pemphigus vulgaris, cirrhosis, primary biliary cirrhosis, idiopathic pulmonary fibrosis, myositis, dermatomyositis, juvenile dermatomyositis, polymyositis, celiac disease, celiac sprue dermatitis, immunoglobulin A nephropathy, Henoch-Schonlein purpura, atopic dermatitis, psoriasis, psoriasis vulgaris, psoriasis arthropathica, Graves' disease, Graves' ophthalmopathy, scleroderma, systemic scleroderma, progressive systemic scleroderma, diffuse scleroderma, localized scleroderma, Crest syndrome, asthma, primary biliary cirrhosis, Hashimoto's thyroiditis, primary myxedema, sympathetic ophthalmia, autoimmune inner ear disease, autoimmune uveitis, autoimmune chronic active hepatitis, ankylosing spondylitis, panarteritis nodosa, polyarteritis nodosa, Wegener's granulomatosis, microscopic polyangiitis, bullous skin disorders, pemphigoid, bullous pemphigoid, cicatricial pemphigoid, vitiligo, atopic eczema, eczema, chronic urticaria, autoimmune urticaria, hypocomplementemic urticarial vasculitis, alopecia areata, alopecia universalis, alopecia totalis, Devic's disease, pernicious anemia, childhood autoimmune hemolytic anemia, idiopathic autoimmune hemolytic anemia, refractory or chronic Autoimmune Cytopenias, Prevention of development of Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A, Cold agglutinin disease, Neuromyelitis Optica, idiopathic pericarditis, anti-synthetase syndrome, PAPA Syndrome, adult and juvenile Still's disease, cryopyrin associated periodic syndrome, Muckle-Wells syndrome, Schnitzler's syndrome, autoimmune retinopathy, and age-related macular degeneration. 20. The method according to claim 19, wherein the treating comprises treatment of the autoimmune disease without global immunosuppression. 21. The method of claim 19, wherein the subject did not previously respond to treatment with TNF blockers.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (150)
Tkachuk Zenovy (Kiev SUX) Kvasyuk Eugeny (Kiev SUX) Matsuka Gennady (Kiev SUX) Mikhailopulo Igor (Kiev SUX), (2′-5′) oligoadenylate analogues useful as inhibitors of host-v5.-graft response.
Suhadolnik Robert J. (Roslyn PA) Pfleiderer Wolfgang (Constance DEX), 2′,5′-phosphorothioate oligoadenylates and their covalent conjugates with polylysine.
Summerton James E. (Corvallis OR) Weller Dwight D. (Corvallis OR) Stirchak Eugene P. (Corvallis OR), Alpha-morpholino ribonucleoside derivatives and polymers thereof.
Lin, Shih-Yao; Lin, Leewen; Tsai, Yu-Ying, Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same.
Sass, Philip M.; Nicolaides, Nicholas C.; Grasso, Luigi; Li, Jian; Chao, Qimin; Routhier, Eric; Ebel, Wolfgang, Antigenic GM-CSF peptides and antibodies to GM-CSF.
Cook Phillip D. (Carlsbad CA) Sanghvi Yogesh S. (San Marcos CA) Vasseur Jean J. (San Marcos CA) Debart Francoise (Montpellier FRX), Backbone modified oligonucleotide analogues.
Sanghvi Yogesh S. (San Marcos CA) Cook Phillip D. (Vista CA), Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling.
Ladner Robert C. (Iamsville MD), Computer based system and method for determining and displaying possible chemical structures for converting double- or m.
Winter Gregory Paul (Cambridge GB3) Duncan Alexander Robert (Wimbledon GBX) Burton Dennis Raymond (Sheffield GB3), DNA encoding antibodies with altered effector functions.
Baxter Anthony D. (Northwich GB2) Baylis Eric K. (Stockport GB2) Collingwood Stephen P. (Westhoughton GB2) Taylor Roger J. (Stretford GB2) De Mesmaeker Alain (Kanerkinden CHX) Schmit Chantal (Basel C, Dinucleoside phosphinates and their pharmaceutical compositions.
Ladner Robert C. (Ijamsville MD) Guterman Sonia K. (Belmont MA) Roberts Bruce L. (Milford MA) Markland William (Milford MA) Ley Arthur C. (Newton MA) Kent Rachel B. (Boxborough MA), Directed evolution of novel binding proteins.
Ladner Robert C. (Ijamsville MD) Guterman Sonia K. (Belmont MA) Roberts Bruce L. (Milford MA) Markland William (Milford MA) Ley Arthur C. (Newton MA) Kent Rachel B. (Boxborough MA), Directed evolution of novel binding proteins.
Queen Cary L. (Los Altos CA) Co Man Sung (Cupertino CA) Schneider William P. (Mountain View CA) Landolfi Nicholas F. (Milpitas CA) Coelingh Kathleen L. (San Francisco CA) Selick Harold E. (Belmont CA, Humanized immunoglobulins.
de Jaeger Nikolaas C. J. (Hove BEX) Monbaliu Marcel J. (Mortsel BEX) Noppe Marcus J. M. (Kalmthout BEX) Konings Frank J. (Antwerpen BEX), Immunoassay using colorable latex particles.
Ladner Robert C. (Ijamsville MD) Bird Robert E. (Rockville MD) Hardman Karl (Chevy Chase MD), Immunotheraphy using single chain polypeptide binding molecules.
Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke She L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke She L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke Shee L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
La Zor Clair G. (13054 Rose St. Cerritos CA 90701), Instrument for locating faults in aircraft passenger reading light and attendant call control system.
Low Philip S. (West Lafayette IN) Horn Mark A. (West Lafayette IN) Heinstein Peter F. (West Lafayette IN), Method for enhancing transmembrane transport of exogenous molecules.
Loughrey Helen C. (Vancouver CAX) Cullis Pieter R. (Vancouver CAX) Bally Marcel B. (Bowen Island CAX) Choi Lewis S. (Burnaby CAX), Method for protein-liposome coupling.
Ling Victor (Toronto CAX) Kartner Norbert (Ajax CAX), Method for selecting hybridomas producing antibodies specific to the P-glycoprotein cell suface antigen and a cDNA clone.
McCafferty John,GBX ; Pope Anthony Richard,GBX ; Johnson Kevin Stuart,GBX ; Hoogenboom Henricus Renerus Jacobus Mattheus,GBX ; Griffiths Andrew David,GBX ; Jackson Ronald Henry,GBX ; Holliger Kaspar , Methods for producing members of specific binding pairs.
McCafferty John,GBX ; Pope Anthony Richard,GBX ; Johnson Kevin Stuart,GBX ; Hoogenboom Henricus Renerus Jacobus Mattheus,GBX ; Griffiths Andrew David,GBX ; Jackson Ronald Henry,GBX ; Holliger Kaspar , Methods for producing members of specific binding pairs.
Matteucci Mark (Burlingame CA) Jones Robert J. (Daly City CA) Munger John (San Francisco CA), Modified internucleoside linkages having one nitrogen and two carbon atoms.
Fanger Michael W. (Lebanon NH) Guyre Paul M. (Hanover NH) Anderson Clark L. (Columbus OH), Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Ts\o Paul O. P. (2117 Folkstone Rd. Lutherville MD 21093) Miller Paul S. (225 Hopkins Rd. Baltimore MD 21212), Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof.
Meyer ; Jr. Rich B. (Woodinville WA) Adams A. David (Snohomish WA) Petrie Charles R. (Woodinville WA), Oligo (aa
상세보기
Letsinger Robert L. (Wilmette IL) Gryaznov Sergei M. (San Mateo CA), Oligodeoxyribonucleotides including 3′-aminonucleoside-phosphoramidate linkages and terminal 3′-amino groups.
Bischofberger Norbert (San Carlos CA) Kent Ken (Mountain View CA) Wagner Rick (Burlingame CA) Buhr Chris (Daly City CA) Lin Kuei-Ying (Fremont CA), Oligonucleotide analogs capable of passive cell membrane permeation.
Weis Alexander Ludvik (Berwyn PA) Hausheer Frederick Herman (San Antonio TX) Chaturvedula Prasad Venkata Chala (Exton PA) Delecki Daniel Joseph (Radnor PA) Cavanaugh ; Jr. Paul Francis (West Chester , Oligonucleotide analogues containing phosphate diester linkage substitutes, compositions thereof, and precursor dinucleo.
Imbach Jean-Louis (Montpellier FRX) Gosselin Gilles J. M. (Montpellier FRX), Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon.
Spielvogel Bernard F. (Raleigh NC) Sood Anup (Durham NC) Hall Iris H. (Chapel Hill NC) Shaw Barbara R. (Durham NC), Oligoribonucleoside and oligodeoxyribonucleoside boranophosphates.
Maddry Joseph A. (Birmingham AL) Reynolds Robert C. (Birmingham AL) Secrist John A. (Birmingham AL) Montgomery John A. (Birmingham AL) Crooks Peter A. (Lexington KY), Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages.
Caruthers Marvin H. (Boulder CO) Marshall William S. (Boulder CO) Brill Wolfgang (Freiburg DEX) Nielsen John (Horsholm DKX), Polynucleotide phosphorodithioate.
Axel Richard (New York NY) Wigler Michael H. (Cold Spring Harbor NY) Silverstein Saul J. (Irvington NY), Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials.
Axel Richard (New York NY) Wigler Michael H. (Cold Spring Harbor NY) Silverstein Saul J. (Irvington NY), Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials.
Axel Richard (New York NY) Wigler Michael H. (Cold Spring Harbor NY) Silverstein Saul J. (Irvington NY), Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials.
Huston James S. (Newton MA) Charette Marc F. (West Roxbury MA) Cohen Charles M. (Medway MA) Crea Roberto (Boston MA) Keck Peter C. (Millbury MA) Oppermann Hermann (Medway MA) Rueger David C. (West Ro, Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage.
Griffiths Andrew David,GBX ; Hoogenboom Hendricus Renerus Jacobus Mattheus,GBX ; Marks James David ; McCafferty John,GBX ; Winter Gregory Paul,GBX ; Grigg Geoffrey Walter,AUX, Production of anti-self antibodies from antibody segment repertoires and displayed on phage.
Griffiths, Andrew David; Hoogenboom, Hendricus Renerus Jacobus Mattheus; Marks, James David; McCafferty, John; Winter, Gregory Paul; Grigg, Geoffrey Walter, Production of anti-self antibodies from antibody segment repertoires and displayed on phage.
Griffiths, Andrew David; Hoogenboom, Hendricus Renerus Jacobus Mattheus; Marks, James David; McCafferty, John; Winter, Gregory Paul; Grigg, Geoffrey Walter, Production of anti-self antibodies from antibody segment repertoires and displayed on phage.
Griffiths, Andrew David; Hoogenboom, Hendricus Renerus Jacobus Mattheus; Marks, James David; McCafferty, John; Winter, Gregory Paul; Grigg, Geoffrey Walter, Production of anti-self antibodies from antibody segment repertoires and displayed on phage.
Griffiths, Andrew David; Hoogenboom, Hendricus Renerus Jacobus Mattheus; Marks, James David; McCafferty, John; Winter, Gregory Paul; Grigg, Geoffrey Walter, Production of anti-self antibodies from antibody segment repertories and displayed on phage.
Griffiths, Andrew David; Hoogenboom, Hendricus Renerus Jacobus Mattheus; Marks, James David; McCafferty, John; Winter, Gregory Paul; Grigg, Geoffrey Walter, Production of anti-self bodies from antibody segment repertories and displayed on phage.
Surani Azim M. (Cambridge GB3) Neuberger Michael S. (Cambridge GB3) Bruggemann Marianne (Cambridge GB3), Production of antibodies from transgenic animals.
Rostoker Michael D. (Boulder Creek CA) Stelliga D. Tony (Pleasanton CA) Paolino Dave (Andover MA) Engelse Willem A. H. (Townsend MA), Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (C.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
Eppstein Deborah A. (Los Altos CA) Fraser-Smith Elizabeth B. (Los Altos CA) Matthews Thomas R. (Los Gatos CA), Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides.
Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
Summerton James E. (Corvallis OR) Weller Dwight D. (Corvallis OR), Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.